Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters
Crossref DOI link: https://doi.org/10.1186/s12885-017-3403-5
Published Online: 2017-06-15
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
McDonnell, Alison M.
Cook, Alistair
Robinson, Bruce W. S.
Lake, Richard A.
Nowak, Anna K.
Funding for this research was provided by:
Pfizer Australia (AU)
Insurance Commission of Western Australia
Cancer Council of Western Australia
National Health and Medical Research Council
